Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes

Maria Kavallaris, Dennis Y.S. Kuo, Catherine A. Burkhart, Donna Lee Regl, Murray D. Norris, Michelle Haber, Susan Band Horwitz

Research output: Contribution to journalArticle

495 Scopus citations

Abstract

The treatment of advanced ovarian cancer with taxol is hindered by the development of drug resistance. The cellular target for taxol is the microtubule that is stabilized by the drug. Taxol preferentially binds to the β subunit of tubulin of which there are six distinct isotypes in mammalian cells. We have used highly specific oligonucleotides and polymerase chain reaction to analyze expression of all six β-tubulin genes. Human lung cancer cells (A549) were selected in 12 and 24 nM taxol resulting in cell lines that were 9- and 17-fold resistant, respectively. These cells displayed an altered ratio of classes I, II, III, and IVa β-tubulin isotypes. Ovarian tumors, seven untreated primary and four taxol-resistant tumor-bearing ascites, displayed significant increases (P < 0.005) in classes I (3.6-fold), III (4.4-fold), and IVa (7.6-fold) isotypes in the taxol-resistant samples as compared with untreated primary ovarian tumors. The increased expression appears to be related to the resistance phenotype, as the basal levels of the class III and IVa isotypes in the untreated tumors were extremely low. This is the first report of altered expression of specific β-tubulin genes in taxol-resistant ovarian tumors and we propose that the latter may play a role in clinical resistance to taxol.

Original languageEnglish (US)
Pages (from-to)1282-1293
Number of pages12
JournalJournal of Clinical Investigation
Volume100
Issue number5
DOIs
StatePublished - Sep 1 1997

    Fingerprint

Keywords

  • Carcinoma
  • Drug resistance
  • Lung
  • Microtubules
  • Polymerase chain reaction

ASJC Scopus subject areas

  • Medicine(all)

Cite this